Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia

Andrey Sivkov1*, Natalya Chernus2, Roman Gorenkov3,4, Sergey Sivkov1, Svetlana Sivkova5 and Tamara Savina5

Abstract

Background: To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia.

Methods: The study consists of 180 patients, aged 40–75 years, with hyperlipidemia. All patients were divided into two equal groups: patients with different SLCO1B1 (521CC, 521CT and 521TT) and MDR1 (3435CC, 3435TC and 3435TT) genotypes. Each group was divided into rosuvastatin-treated, atorvastatin-treated and simvastatin-treated subgroups. The lipid-lowering effect of statins was assessed by tracing changes in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels.

Results: The use of statins over a 4-month period led to substantial reductions in TC and LDL-C levels. The hypolipidemic effect of studied agents was seen in both groups. However, it was less pronounced in patients with 521CC genotype. No statistically significantly differences were found between carriers of 3435TT, 3435CT and 3435CC genotypes.

Conclusions: The lipid-lowering efficacy of rosuvastatin was higher compared to other two statins. Patients with SLCO1B1 521CC genotype are more likely to encounter a decrease in the hypolipidemic effect of statins. Such a risk should be considered when treating this category of patients. MDR1 polymorphism had no significant effect on statin efficacy.

Keywords: Cardiovascular diseases, Hyperlipidemia, Cholesterol, Low-density lipoprotein, Hydroxymethylglutaryl-CoA reductase inhibitors, Pharmacogenetics
Introduction
Dyslipidemia and atherosclerosis are known to play a vital role in the development of coronary heart disease and arterial hypertension [1]. The atherosclerotic process is associated with elevated levels of cholesterol and low-density lipoproteins (LDLs) [2].

The main group of drugs used to treat dyslipidemia are statins [3, 4]. At present, the most commonly used statins are simvastatin, rosuvastatin and atorvastatin [5, 6]. The indication for statin therapy as primary prevention of cardiovascular complications is having a high level of cholesterol in the blood [7].

Statins are mandatory in the secondary prevention of myocardial infarction, and a high-dose statin therapy is justified in the treatment of patients with an acute coronary syndrome [8–10]. However, such treatment often has unwanted side effects, such as constipation, less often diarrhea, rhabdomyolysis, liver dysfunction, pancreatitis, myopathy, dizziness, and more [11–13]. Despite the proven efficacy of statins, their effectiveness and toxicity can vary from patient to patient [14]. The efficacy and side effects of statins can correlate with the presence of genetic polymorphisms, which affect the pharmacokinetics and pharmacodynamics of lipid-lowering agents. However, little studies in pharmacogenetics have been devoted to the identification of genetic markers for statin safety. Among the observations, one is that SLCO1B1 c.521 T > C polymorphism is most associated with myopathy and rhabdomyolysis [15–18]. Hence, more studies are required about the effect of genetic polymorphisms of transporters involved in lipid transportation on statin efficacy.

Organic anion (OATP) transporters actively capture and transport statins into hepatocytes. All statins are substrates for organic anion-transporting polypeptides 1B1 (OATP1B1), the transport activity of which is associated with the SLCO1B1 gene. At the same time, OATP1B1 is the only transporter of simvastatin. Rosuvastatin is a substrate for OATP1B3 and OATP2B1, and atorvastatin is a substrate for OATP2B1 [19]. Medical literature provides contradictory data on the effect of genetic polymorphism of OATP transporters on the lipid response to statin treatment in patients of different ethnicities. While some studies hold that it can affect the pharmacodynamic effect of statins [20–22], other studies give no evidence to support such an effect [23].

Hepatobiliary and renal-urinary transport of statins and their metabolites occurs largely through the ATP-binding cassette (ABC) transport protein P-glycoprotein (ABCB1), the transport function of which is associated with the MDR1 gene [24]. P-glycoprotein is responsible for the excretion of statins and prevents penetration into the systemic circulation. It also limits reabsorption by the kidneys. C3435T polymorphism in the MDR1 gene causes the dysfunction of P-glycoprotein, leading to variability in the pharmacokinetic profile of statins and, consequently, affects their effectiveness [24, 25].

Given the above, there is a need to investigate statin efficacy with respect to C521T and C3435T polymorphism in the SLCO1B1 and MDR1 genes. This study aims to determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia.

Materials and methods
The study of statin efficacy and genetic polymorphism involved 180 patients (43 male and 137 female) with hyperlipidemia (HDH), aged 40 to 75 years. Patients with these disorders were excluded from the study: secondary HDH, heart failure (NYHA class III–IV), symptomatic hypertension, elevated hepatic enzymes (> 50% above), kidney diseases (including kidney failure), and statin intolerance.

The carriage of C3435T and T521C polymorphic variants was determined by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Studies were performed on cubital vein blood samples. Based on the results of the assay, all patients were divided into two equal groups (Fig. 1).

Group A consists of patients with C521T polymorphism in the SLCO1B1 gene, which encodes OATP1B1. Group B encompasses patients with MDR1 C3435T genotypes. In each group, patients with different types of genotypes were randomly divided into three subgroups of 30 patients based on the type of drug they were given. Subgroups A1 and B1 received rosuvastatin therapy. Subgroups AII and BII received atorvastatin therapy. Subgroups AIII and BIII underwent simvastatin therapy. The details of clinical and demographic data of all patients are presented in Table 1.

The initial dosage of studied statins (Rosuvastatin, Atorvastatin and Simvastatin) was 10 mg per day. After four months of therapy, the dosage level was 40 mg per day.

The blood samples were used to measure the concentration of each of the following lipid parameters: total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and high-density lipoprotein cholesterol (HDL-C). Lipid profiles were measured spectrophotometrically. HDL-C concentration was determined after precipitation of LDL and VLDL in blood serum using phosphotungstic acid. The lipid-lowering efficacy of statins with respect to genetic polymorphism of drug transporters was evaluated by the change in TC and LDL-C levels.
Statistical data analysis was carried out in EXEL using generally accepted methods. The paired Wilcoxon test was used to find statistically significant differences between baseline and post-treatment data. The Mann-Whitney test was used to measure the statistical significance of differences between baseline and follow-up levels of total and LDL cholesterol in subgroups. The statistical significance of differences between patients with different genotypes was established using one-way analysis of variance (ANOVA). Differences were considered statistically significant at $p < 0.05$. Absolute differences are presented as means with their standard deviations ($M \pm SD$), and relative differences are expressed as percentages.

### Results

The distribution of the $SLCO1B1$ C521T and $MDR1$ C3435T polymorphism genotypes is shown in Table 2. Among the genotypes with the C521T polymorphic marker of the $SLCOB1$ - OATP - C gene, there was a predominance of patients with the genotype 521TT. It makes up 50% of all cases in Subgroup AI, 53.3% of all cases in Subgroup AII, and 40% of all cases in Subgroup AIII. The 521CC and 521CT genotypes were less prevalent. Among the genotypes with the C3435T polymorphic marker of the $MDR1$ gene, there was a predominance of patients with the genotype 3435TC. It makes up 50% of all cases in Subgroup BI, 46.7% of all cases in Subgroup BII, and 50% of all cases in Subgroup BIII.

### Table 1: Demographic and clinical characteristics of patients with $SLCO1B1$ C521T polymorphism (Group A) and $MDR1$ C3435T polymorphism (Group B) who underwent statin treatment (Rosuvastatin, Atorvastatin and Simvastatin)

| Characteristic               | Rosuvastatin Subgroup A I (n=30) | Rosuvastatin Subgroup B I (n=30) | Atorvastatin Subgroup A II (n=30) | Atorvastatin Subgroup B II (n=30) | Simvastatin Subgroup A III (n=30) | Simvastatin Subgroup B III (n=30) |
|-----------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Sex, male/female            | 6 (20%)/ 24 (80%)                | 8 (26,6%)/ 22 (73,4%)            | 7 (23%)/ 23 (77%)                | 9 (30%)/ 21 (70%)                | 5 (16,7%)/ 25 (83,3%)           | 8 (26,6%)/ 22 (73,4%)           |
| Average age, years ($M \pm m$) | 55.2 ± 1.47                    | 54.7 ± 1.42                     | 57.3 ± 1.59                     | 58.2 ± 1.61                     | 55.9 ± 1.63                     | 56.8 ± 1.54                     |
| Hyperlipoproteinemia Type Ia | 16 (53%)                        | 18 (60%)                        | 17 (56,7%)                      | 19 (63,3%)                      | 18 (60%)                        | 20 (66,7%)                      |
| Hyperlipoproteinemia Type IIb| 14 (46,7%)                      | 12 (40%)                        | 13 (43,3%)                      | 11 (36,7%)                      | 12 (40%)                        | 10 (33,3%)                      |
| Arterial hypertension Degree I–II | 25 (83,3%)                  | 24 (80%)                        | 29 (96,7%)                      | 27 (90%)                        | 30 (100%)                       | 28 (93,3%)                      |
The 521CC and 521CT genotypes were less prevalent.

At 4-month followed up, in general the rosuvastatin-treated group with \( \text{SLCO1B1} \) C521T polymorphism (AI) exhibited a statistically significant reduction of TC (30.7%, \( P < 0.001 \)) and LDL-C levels (38.0%, \( P < 0.001 \)). Subgroups with different \( \text{SLCOB1} \) genotypes also showed a significant decrease in TC and LDL-C levels (\( P < 0.001 \)). However, 521CC genotype carriers had much less improvement in TC (19.6% versus 35.1 and 32.2%, \( p < 0.01 \)) and LDL-C (31.9% versus 41.0% and 37.9%, \( P < 0.05 \)) than in patients with other genotypes.

Patients treated with simvastatin (AIII) showed significantly lower levels of TC and LDL-C than at baseline. While TC levels decreased by 28.9%, LDL-C levels fell by 36.9%, \( P < 0.001 \). The genotype-specific trend was similar to those in other two \( \text{SLCOB1} \)-related subgroups. Although a significant decrease in TC and LDL-C levels (\( P < 0.001 \)) was seen in all patients, regardless of the \( \text{SLCOB1} \) genotype, patients carrying 521CC genotype showed lesser improvement (19.3%) compared with genotypes 521TT (32.2%) and 521CT (40.1%). Baseline and follow-up levels of total cholesterol and LDL cholesterol in HLP patients with different \( \text{SLCO1B1} \) genotypes who underwent Rosuvastatin, Atorvastatin and Simvastatin therapy (Subgroups AI, AII, and AIII) are shown in Fig. 2 and Table 3.

For patients with \( \text{MDR1} \) C3435T genotypes (Group B), the following was observed. Subgroup BI (rosuvastatin-treated patients) exhibited a statistically significant reduction of TC (33.3%) and LDL-C levels (38.2%, \( P < 0.001 \)). Although a significant decrease (\( P < 0.001 \)) was observed in all patients, regardless of the \( \text{SLCOB1} \) genotype, patients carrying 3435CC genotype had slightly higher levels of TC and LDL-C, though there were significant decreases in levels of TC (26.2%, \( p < 0.001 \)) and LDL-C (36.9%, \( p < 0.001 \)) in atorvastatin-treated patients (AII). As with Subgroup AI, patients with different \( \text{SLCOB1} \) genotypes all exhibited a significant reduction of TC and LDL-C levels (\( p < 0.01 \)). However, 521CC genotype carriers had much less improvement in TC (19.7% vs 27.3 and 27.1%, \( P < 0.01 \)) and LDL-C (29.5% vs 39.1 and 36.3%, \( P < 0.02 \)) levels than in patients with other genotypes.

### Table 2

The prevalence of \( \text{SLCO1B1} \) C521T genotypes (Group A) and \( \text{MDR1} \) C3435T genotypes (Group B) in patients with HDH who underwent statin treatment (Rosuvastatin, Atorvastatin and Simvastatin)

| Subgroup        | Genotypes | SLCO1B1 C521T (Group A) |          |          |          |
|-----------------|-----------|-------------------------|----------|----------|----------|
|                 |           | 521CC | 521TT | 521CT |
| Subgroup AI     |           |       |       |       |
| Rosuvastatin, n=30 | 6 (20.0%) | 15 (50.0%) | 9 (30.0%) |
| Subgroup AII    |           |       |       |       |
| Atorvastatin, n=30 | 6 (20.0%) | 16 (53.3%) | 8 (26.7%) |
| Subgroup AIII   |           |       |       |       |
| Simvastatin, n=30 | 8 (26.7%) | 12 (40.0%) | 10 (33.3%) |

| Subgroup        | Genotypes | MDR1 C3435T (Group B) |          |          |          |
|-----------------|-----------|-----------------------|----------|----------|----------|
|                 |           | 3435CC | 3435TT | 3435CT |
| Subgroup BI     |           |       |       |       |
| Rosuvastatin, n=30 | 8 (26.7%) | 7 (23.3%) | 15 (50.0%) |
| Subgroup BII    |           |       |       |       |
| Atorvastatin, n=30 | 9 (30.0%) | 7 (23.3%) | 14 (46.7%) |
| Subgroup BIII   |           |       |       |       |
| Simvastatin, n=30 | 7 (23.3%) | 8 (26.7%) | 15 (50.0%) |

![Fig. 2](image-url) Baseline and follow-up levels of total cholesterol and LDL cholesterol in HLP patients with different \( \text{SLCO1B1} \) genotypes who underwent Rosuvastatin, Atorvastatin and Simvastatin therapy (Subgroups AI, AII, AIII)
statistically insignificant ($P > 0.05$), compared with 3435TT and 3435TC carriers. There were significant decreases in levels of TC (28.5%, $P < 0.001$) and LDL-C (36.4%, $P < 0.001$) in Subgroup BII where patients were treated with atorvastatin. Subgroups with different MDR1 genotypes all showed a significant decrease in TC and LDL-C levels from baseline ($P < 0.001$). No statistically significant differences were found between the subgroups ($P > 0.05$).

Patients treated with simvastatin (Subgroup BIII) exhibited a statistically significant reduction of TC (29.6%, $P < 0.001$) and LDL-C levels (38.1%, $P < 0.001$). In this Subgroup, patients having different MDR1 genotypes showed a significant improvement from baseline ($P < 0.001$), and no statistically significant differences were found between the subgroups ($P > 0.05$). Baseline and follow-up levels of total cholesterol and LDL cholesterol in HLP patients with different MDR1 genotypes who underwent Rosuvastatin, Atorvastatin and Simvastatin therapy (Subgroups BI, BII, BIII) are shown in Fig. 3 and Table 4.

No side effects were reported. The analysis reveals that statin treatment is less effective in lowering TC and LDL-C levels with patients who carry the $SLCO1B1$ CC

### Table 3
Baseline and follow-up levels of total cholesterol and LDL cholesterol in HLP patients with different $SLCO1B1$ genotypes who underwent Rosuvastatin, Atorvastatin and Simvastatin therapy (Subgroups AI, AII, AIII)

| Subgroup          | $SLCO1B1$ genotypes | Total cholesterol (mmol/L) | LDL cholesterol (mmol/L) |
|-------------------|---------------------|---------------------------|-------------------------|
|                   |                     | Baseline | 4-month follow-up | Change     | Baseline | 4-month follow-up | Change     |
| Subgroup A (Rosuvastatin) | 521CC ($n = 6$) | 7.15 ± 0.14 | 5.75 ± 0.16* | −19.6% | 4.95 ± 0.15 | 3.37 ± 0.14** | −31.9% |
|                   | 521TT ($n = 15$)  | 7.10 ± 0.14 | 4.61 ± 0.15*** | −35.1% | 4.96 ± 0.17 | 2.93 ± 0.15*** | −41.0% |
|                   | 521CT ($n = 9$)   | 7.17 ± 0.15 | 4.86 ± 0.17*** | −32.2% | 4.99 ± 0.18 | 3.10 ± 0.19*** | −37.9% |
|                   | Mean ($n = 30$)   | 7.13 ± 0.11 | 4.94 ± 0.14*** | −30.7% | 4.97 ± 0.17 | 3.08 ± 0.16*** | −38.0% |
| Subgroup B (Atorvastatin) | 521CC ($n = 6$) | 7.17 ± 0.17 | 5.74 ± 0.21* | −19.7% | 5.12 ± 0.27 | 3.61 ± 0.28** | −29.5% |
|                   | 521TT ($n = 16$)  | 7.19 ± 0.14 | 5.21 ± 0.19*** | −27.3% | 5.09 ± 0.19 | 3.10 ± 0.22*** | −39.1% |
|                   | 521CT ($n = 8$)   | 7.19 ± 0.15 | 5.24 ± 0.18*** | −27.1% | 4.99 ± 0.20 | 3.18 ± 0.27*** | −36.3% |
|                   | Mean ($n = 30$)   | 7.15 ± 0.18 | 5.29 ± 0.25*** | −26.2% | 5.06 ± 0.26 | 3.19 ± 0.25*** | −36.9% |
| Subgroup B (Simvastatin) | 521CC ($n = 8$) | 7.16 ± 0.21 | 5.78 ± 0.22* | −19.3% | 5.13 ± 0.19 | 3.67 ± 0.17** | −28.5% |
|                   | 521TT ($n = 12$)  | 7.12 ± 0.19 | 4.83 ± 0.18*** | −32.2% | 5.14 ± 0.17 | 3.08 ± 0.18*** | −40.1% |
|                   | 521CT ($n = 10$)  | 7.11 ± 0.20 | 4.79 ± 0.21*** | −32.6% | 5.09 ± 0.21 | 3.07 ± 0.16*** | −39.7% |
|                   | Mean ($n = 30$)   | 7.13 ± 0.18 | 5.07 ± 0.23*** | −28.9% | 5.12 ± 0.18 | 3.23 ± 0.23*** | −36.9% |

Note: *$p < 0.05$, **$p < 0.01$, and ***$p < 0.001$ — significant differences from baseline
genotype as compared with patients having TT and CT variants. As for patients with *MDR1* C3435T genotypes, there were no statistically significant differences between the studied genotypes.

**Discussion**

Over a 4-month period, the present study determined the T521C genotype frequency and the dynamics of total cholesterol and LDL cholesterol in patients with hyperlipidemia carrying the *SLCO1B1* C521T and *MDR1* C3435T polymorphisms. The study found that patients carrying the CC genotype of the C521T polymorphism experience a less pronounced decrease in total cholesterol and LDL cholesterol levels during statin therapy than TT and CT genotype carriers, regardless of the drug used. This finding indicates that statin therapy is less effective with T521CC genotype carriers. No statistically significant differences were found between patients with TT, CT, and CC genotypes of the C3435T polymorphism.

Genetic polymorphism of OATP1B1 transporters causes changes in the pharmacodynamics of statins [24]. The first retrospective study about the relationship between genetic *SLCO1B1* polymorphism and lipid-lowering response to statins was carried out among 66 patients in Japan [26]. The patients received pravastatin, atorvastatin, and simvastatin. The results show that individuals with variant C allele had lesser improvement in TC and LDL-C levels compared to TT homozygotes. A study investigating the pharmacodynamics and pharmacokinetics of atorvastatin in 21 Russians found a significant association between *SLCO1B1* polymorphism (CC genotype) and a magnitude of LDL reduction [27].

A meta-analysis of 8 studies that encompass 2012 wild-type patients (TT) and 526 carriers of the variant C allele (CT and CC genotypes) found no significant difference in the lipid-lowering efficacy of statins between *SLCO1B1* genotypes [28]. However, the study did show an improved lipid-lowering efficacy of simvastatin in TT genotype carriers [28]. Another meta-analysis reveals no association between *SLCO1B1* polymorphism and the lipid-lowering efficacy of statins [29]. However, it also shows a stronger effect of the TT variant in the LDL-lowering response to statins and weaker effects in CT and CC genotype carriers. This finding indicates a decrease in the lipid-lowering effect of statins under low OATP1B1 activity. The said meta-analysis also provides evidence of ethnic differences in statins efficacy. For instance, differences seen in the magnitude of LDL reduction between wild (TT) and variant genotype (CT and CC) cases were more pronounced among non-Asian patients.

Current results obtained with the cohort of Russian patients coincide with the latest meta-analysis [20]. In both cases, patients with TT genotype had significantly greater therapy outcomes than CC genotype carriers, regardless of the statins used. At the same time, patients with CT genotype also had substantial improvements in LDL levels, almost as great as with patients carrying the TT genotype.

Given the absence of adverse drug reactions in the present study, no consideration as made for the relationship between *SLCO1B1* polymorphism and statin-induced complications. The available literature, however, highlights that variant genotype, especially CC ones, increase the risk of myopathy in patients who take high doses of statins [30, 31]. It is likely that the risk of developing myopathy is more common with lipophilic drugs, such as simvastatin and atorvastatin [32, 33].

| Subgroup | MDR1 genotypes | Total cholesterol (mmol/L) | LDL cholesterol (mmol/L) |
|----------|-----------------|----------------------------|--------------------------|
|          |                 | Baseline | 4-month follow-up | Change | Baseline | 4-month follow-up | Change |
| Subgroup BI (Rosuvastatin) | 3435CC (n = 8) | 7.08 ± 0.14 | 4.59 ± 0.17* | −35.1% | 5.10 ± 0.17 | 3.31 ± 0.19* | −35.1% |
|         | 3435TT (n = 7) | 7.15 ± 0.17 | 4.70 ± 0.16* | −34.3% | 5.05 ± 0.18 | 3.11 ± 0.21* | −38.4% |
|         | 3435CT (n = 15) | 7.16 ± 0.16 | 4.88 ± 0.15* | −31.8% | 4.92 ± 0.19 | 2.96 ± 0.20* | −38.8% |
| Mean (n = 30) | 7.14 ± 0.13 | 4.76 ± 0.14* | −33.3% | 5.00 ± 0.15 | 3.09 ± 0.17* | −38.2% |
| Subgroup BII (Atorvastatin) | 3435CC (n = 9) | 7.13 ± 0.18 | 5.02 ± 0.22* | −29.6% | 4.92 ± 0.19 | 3.29 ± 0.21* | −33.1% |
|         | 3435TT (n = 7) | 7.14 ± 0.17 | 5.15 ± 0.24* | −27.9% | 5.03 ± 0.18 | 3.35 ± 0.20* | −33.4% |
|         | 3435CT (n = 14) | 7.17 ± 0.16 | 5.14 ± 0.25* | −28.3% | 4.98 ± 0.21 | 2.98 ± 0.22* | −30.1% |
| Mean (n = 30) | 7.15 ± 0.15 | 5.11 ± 0.23* | −28.5% | 4.97 ± 0.17 | 3.16 ± 0.19* | −36.4% |
| Subgroup BIII (Simvastatin) | 3435CC (n = 7) | 7.16 ± 0.23 | 5.14 ± 0.31* | −28.9% | 5.14 ± 0.20 | 3.33 ± 0.23* | −35.1% |
|         | 3435TT (n = 8) | 7.21 ± 0.21 | 5.07 ± 0.32* | −29.7% | 5.07 ± 0.19 | 3.10 ± 0.25* | −38.9% |
|         | 3435CT (n = 15) | 7.17 ± 0.17 | 5.01 ± 0.28* | −30.1% | 5.13 ± 0.18 | 3.12 ± 0.24* | −39.1% |
| Mean (n = 30) | 7.18 ± 0.19 | 5.05 ± 0.29* | −29.6% | 5.11 ± 0.16 | 3.16 ± 0.21* | −38.1% |

Note: *p < 0.001 — significant differences from baseline

*Table 4* Baseline and follow-up levels of total cholesterol and LDL cholesterol in HLP patients with different MDR1 genotypes who underwent Rosuvastatin, Atorvastatin and Simvastatin therapy (Subgroups BI, BII, BIII)
findings urged the Food and Drug Administration (FDA, USA) in 2011 to recommend limiting the use of the maximum doses of simvastatin (80 mg) to keep the risk of myopathy low [34]. Patients with statin-induced myopathy can be classified into three risk groups according to their SLCO1B1 genotype. They are described as normal myopathy risk (TT genotype), intermediate myopathy risk (CT genotype), and high myopathy risk (CC genotype). The Clinical Pharmacogenomics Implementation Consortium Guidelines for SLCO1B1 and Simvastatin-induced Myopathy provide a decision support algorithm for prescribing simvastatin to patients with SLCO1B1*5 genotype [35].

The present study shows no association between statin efficacy and MDR1 C3435T polymorphism in patients with TT genotype. No statistically significant differences were found in TC and LDL-C reduction between carriers of CT and CC genotypes. The existing research, however, provides contradictory data on the role of C3435T polymorphism in the lipid-lowering response to the statins. An early study of simvastatin-treated Brazilians failed to find such a connection [36]. A study conducted in Russia, on the other hand, revealed that TT genotype carriers had significantly greater reductions in TC and LDL-C levels after simvastatin and atorvastatin than carriers of CT and CC genotypes [37]. No relationship was found between MDR1 polymorphism and rosuvastatin efficacy [37–39]. Another study provides evidence that in the presence of MDR1 polymorphism, statins do not increase the risk of myopathy significantly, but they may cause a substantial increase in the risk of muscle toxicity in C-allele carriers if taken for more than 5 months [25].

Statins are widely used in the treatment of cardiovascular diseases, dyslipidemias and atherosclerosis. At the same time, there is a large variability in the lipid-lowering response to statins, which may be associated with pharmacogenetic characteristics. Studies on polymorphism in OATP and ABC transporters show that these transporters play an active role in the absorption and distribution of statins, the role of ABC transporters is less obvious though.

**Comparisons with other studies and what does the current work add to the existing knowledge**

Literature describes a large number of gene polymorphisms that can be considered as potential pharmacogenetic biomarkers of statin-related adverse effects [24]. In practical healthcare, however, pharmacogenetic testing is used to detect just one - the SLCO1B1 C521T polymorphism, as there is evidence that the carriage of the C521CC allelic variant poses a significant risk of unwanted response from the muscular system [27]. Studies investigating the dependence between the SLCO1B1 C521T polymorphism and the pharmacological response to statins provide ambiguous results. Some authors report detecting the worst response among patients with the CC genotype [26, 27, 29]. Meantime, other researchers do not indicate such a connection but report an increased lipid-lowering effect of statins in TT genotype carriers [20, 28]. Data on the relationship between MDR1 C3435T polymorphism and statin therapy are also contradictory [36–38]. The present study confirmed that statins are less effective in patients with the C521CC genotype but failed to demonstrate a statistically significant difference in TC and LDL-C improvement between carriers of different C3435T genotypes.

**Study strength and limitations**

The strength of this study is that it investigates the effect of polymorphism in genes encoding the glycoprotein P and the organic anion transporter C on the efficacy and safety of statin therapy, the most commonly used therapy for hyperlipidemia in Russia. The studies were carried out using standard, well-tested methods. The findings expand our understanding of how important the role of gene polymorphism is in promoting the effectiveness of statin therapy. The limitations of this study are associated with a small sample size. Additionally, the present study did not investigate interactions between various gene polymorphisms regarding statin metabolism and efficacy. Nor did it examine the connection between gene polymorphism and statin-induced complications.

**Conclusions**

The presence of polymorphisms in genes encoding drug transporters, primarily OATP1B1, can significantly affect the individual response to treatment. Patients with SLCO1B1 521CC genotype are more likely than carriers of 521TT and 521CT genotypes to experience a decrease in the hypolipidemic effect of statins. It is also vital to consider that 521CC genotype carriers have a higher risk of developing myopathy when undergoing a high-dose statin therapy. The MDR1 polymorphism had no substantial impact on the effectiveness of statins. The hypolipidemic efficacy of statins was found to be high in both studied groups. Concerns regarding safety were not established. The most pronounced effects were seen after rosuvastatin. In clinical practice, determining T521C genotypes could be a personalized approach to appropriate statin selection for patients with hyperlipidemia. Meantime, this study found no evidence that determining C3435T genotypes in patients with hyperlipidemia is required. Overall, the results of the present study suggest tailoring statin therapy to the type and dose of medication while taking into account the pharmacogenetic aspects.
Acknowledgements

Not applicable.

Authors’ contributions

AS, NC, RG, SS, SS, and TS contributed equally to the experimentation. AS, NC, and RG wrote and edited the article. SS and SS equally designed and conducted the experiment. TS studied scientific literature about the topic. All authors read and approved the final manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

Data will be available on request.

Declarations

Ethics approval and consent to participate

The authors declare that the work is written with due consideration of ethical standards. The study was conducted in accordance with the ethical principles approved by the Human Experiments Ethics Committee of I.M. Sechenov First Moscow State Medical University (Sechenov University) (Protocol No 12 of 12.06.2020). All the participants have given their written informed consent to the participation in the research.

Consent for publication

All the participants have given their consent to the publication of the research results.

Competing interests

The authors declare that they have no competing interests.

Author details

1N.V. Skilfosovsky Institute of Clinical Medicine, Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. 2N.V. Skilfosovsky Institute of Clinical Medicine, Department of Polyclinical Therapy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. 3Institute of Leadership and Health Management, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. 4Federal State Budget Scientific Institution, «The N. A. Semashko National Research Institute of Public Health», Moscow, Russian Federation. 5N.V. Skilfosovsky Institute of Clinical Medicine, Department of Polyclinical Therapy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. 6Department of the Cardiovascular System, Institute of Cardiovascular Physiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation. 7Department of Clinical Medicine, Institute of Cardiovascular Physiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

Received: 30 August 2021 Accepted: 22 October 2021
Published online: 08 November 2021

References

1. Kukës VG. Metabolism of medicinal products: the fundamentals of personalized medicine. GEOTARMED. Moscow, 2008.
2. Kukës VG. Clinical pharmacology. GEOTARMED. Moscow, 2016.
3. Smirnova MD, Ageev FT. Statins — old myths and new facts. RMU. 2017;20: 1421-8.
4. Sukhaterina NA. Dynamics of lipid spectrum and markers of inflammation in hypertensive patients with chronic obstructive pulmonary disease who receive atorvastatin. JAD. 2016;3:68-74.
5. Kukharshuk W, Semenova AE. Correction of hyperlipidemia: statin treatment at post-marketing. The compliance study. JAD. 2015;1:5–11.
6. Nedogoda SV. Rosuvastatin: evidence base and significance for real clinical practice. RMU. 2015;15:866.
7. Ezhov MV, Bilznyuk SA, Aleksieva IA, Vypgodin VA. Prevalence of hypercholesterolemia and statins intake in the outpatient practice of the Russian Federation (ICEBERG study). JAD. 2017;45–17.
8. Barbarash OL, Khashatlap WV, Shibanova IA. A patient after an episode of acute coronary syndrome. Lipid control after the acute coronary syndrome. JAD. 2019;10(2):5-14.
9. Drapkina OM. Statins in acute coronary syndrome. Cardiovasc Ther Prev. 2009;8(5):69-73.
10. Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin–fibrate therapy: safety aspects. Diabetes Obes Metab. 2009;11(2):89–94. https://doi.org/10.1111/j.1463-1326.2008.00917.x.
11. Bays H, Cohen DE, Chalasani N, Harrison SA. The National Lipid Association’s statin safety task force. An assessment by the statin liver safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S57–57. https://doi.org/10.1016/j.jcl.2014.02.011.
12. Goroshko OA, Krasnykh LM, Kukes VG, Zozina VI. Evaluation of coenzyme Q10 redox status as a biomarker of oxidative stress, Bull Scientific Centre Exp Eval Medicin Prod. 2019;9(3):146–52. https://doi.org/10.30899/1991-2919-2019-9-3-146-152.
13. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keidle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101.
14. Leonova MV, Gaysonok OV, Leonov AS. Statins pharmacogenetics: metabolizing enzymes and transporters polymorphisms role. Consilium Medicum. 2018;20(10):20–8. https://doi.org/10.26444/2017-157/2018.10.2-8.
15. Buzkova H, Pechandova K, Danzov V, Vareka T, Perlík F, Zák A, et al. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit. 2012; 18(BR):CR152–7. https://doi.org/10.1260/1421-8693.2012-3272.
16. Hoening MR, Walker PJ, Gumsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011;5(2):91–6. https://doi.org/10.1016/j.jacl.2011.01.001.
17. Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in south-Indian subjects. Indian Heart J. 2018;70(Suppl 3):S120. https://doi.org/10.1016/j.ihj.2018.07.009.
18. Talameh JA, Kitzmiller JP. Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic variants. J Pharmacogenomics Pharmacoproteomics. 2014;5(2):128. https://doi.org/10.14722/2153-0645.1000128.
19. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157-81. https://doi.org/10.1124/pr.110.002857.
20. Rye K, Checha OA, Mazerkina IA, Muslimova OV, Eyu D, Alexandrova TV, et al. Pharmacogenetic approaches to enhancing efficacy and safety of statins as illustrated by the example of atorvastatin. Safety Risk Pharmacother. 2020;8(1):43–51. https://doi.org/10.30895/2312-7821-2020-8-1-43-51.
21. Rumyantseva NA, Kukes VG, Grapov DO. Experience in the implementation of pharmacogenetic testing in clinical practice at the administration of statin group drugs. Analysis of longterm therapy results. Med News North Caucasus. 2019;14(4):646–9. https://doi.org/10.14300/mnnc.2019.14160.
22. Woo HI, Kim SR, Huh W, Ko JW, Lee SY. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Des Devel Ther. 2017;11:1135–46. https://doi.org/10.2147/DDDT.S131487.
23. Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, et al. No impact of SLCO1B1 5217C>T, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014; 41(7):4631–8. https://doi.org/10.1007/s10027-014-3342-z.
24. Kitzmiller JP, Mikulik EB, Daiki AM, Mulkhejeree C, Luzum JA. Pharmacogenomics of statins: understanding susceptibility to adverse effects. PCCM. 2016;69:97–106. https://doi.org/10.2147/PPCM.S86013.
25. Su J, Xu H, Yang J, Yu Q, Yang S, Zhang J, et al. ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. Lipids Health Dis. 2015;14(1):122. https://doi.org/10.1186/s12944-015-0114-2.
26. Tachibana-Imori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, et al. Effect of genetic polymorphisms of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet. 2004;19(5):375–80. https://doi.org/10.2133/dmnpk.19.375.
27. Semenov AV, Sychev DA, Kukes VG. The effect of SLCO1B1 and MDR1 polymorphism on the pharmacokinetics and pharmacodynamics of atorvastatin in patients with primary hypercholesterolemia: a pilot study. Consilium Medicum. 2018;20(10):20–8. https://doi.org/10.26444/2017-157/2018.10.2-8.
pharmacogenetic study. Ration Pharmacother Cardiol. 2008;2(2):47–50. https://doi.org/10.20996/1819-6446-2008-2-2-47-50.

28. Dou Y, Zhu X, Wang Q, Tian X, Cheng J, Zhang E. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med. 2015;35(3):329–35. https://doi.org/10.3343/alm.2015.35.3.329.

29. Dai R, Feng J, Wang Y, Yang Y, Deng C, Tang X, et al. Association between SLCO1B1 S21T>C and 388A>G polymorphisms and statin effectiveness: a meta-analysis. J Atheroscler Thromb. 2015;22(8):796–815. https://doi.org/10.5551/jat.26856.

30. Hou Q, Li S, Li, Li Y, Sun X, Tian H. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine. 2015;94(37)e1268. https://doi.org/10.1097/MD.0000000000001268.

31. Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. SpringerPlus. 2016;5(1):1368. https://doi.org/10.1186/s40064-016-2912-2.

32. Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med. 2014;16(11):810–9. https://doi.org/10.1038/gim.2014.41.

33. Xiang Q, Zhang XD, Mu Y, Wang Z, Liu ZY, Xie QF, et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol. 2021;77(4):569–81. https://doi.org/10.1007/s00228-020-03029-1.

34. US Food and Drug Administration FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm.

35. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. CPT. 2014;96(4):423–8. https://doi.org/10.1038/clpt.2014.125.

36. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. CPT. 2005;78(5):551–8. https://doi.org/10.1016/j.clpt.2005.08.003.

37. Mal GS, Kuvshinova YuA. The use of lipid-lowering agents with the help of genetic markers in patients with coronary artery disease. Ljourn.ru. 2013.3.

38. Bitkina TA, Basevich AV, Rodin VM. Critical points for the production of polymeric microspheres used in X-Ray surgery. Drug Dev Regist. 2020(3):28–35. https://doi.org/10.13388/2305-2066-2020-9-3-28-35.

39. Lugnen B, Dimitrieva MV, Orlova OL, Krasnyuk E, Krasnyuk II Jr, Bokov DQ, et al. Development of a liposomal dosage form based on hydrophobic derivative of indolocarbazole. Drug Dev Regist. 2020(3):21–6. https://doi.org/10.13388/2305-2066-2020-9-3-21-26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.